QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:INVA

Innoviva (INVA) Stock Forecast, Price & News

$13.06
-0.14 (-1.06%)
(As of 06/6/2023 ET)
Compare
Today's Range
$13.03
$13.31
50-Day Range
$11.15
$13.64
52-Week Range
$10.64
$15.67
Volume
648,552 shs
Average Volume
698,768 shs
Market Capitalization
$911.33 million
P/E Ratio
5.70
Dividend Yield
N/A
Price Target
$15.17

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
16.1% Upside
$15.17 Price Target
Short Interest
Bearish
13.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
1.26mentions of Innoviva in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$6.48 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

734th out of 981 stocks

Pharmaceutical Preparations Industry

355th out of 464 stocks


INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Innoviva (NASDAQ:INVA) Upgraded by StockNews.com to Buy
Innoviva Announces Retirement of Board Chairman
Innoviva (NASDAQ:INVA) Stock Price Up 4%
Innoviva (NASDAQ:INVA) Sees Large Volume Increase
Innoviva (NASDAQ:INVA) Shares Gap Up to $12.02
Is Innoviva (INVA) Stock Undervalued Right Now?
See More Headlines

INVA Price History

INVA Company Calendar

Last Earnings
10/27/2021
Today
6/06/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
5
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$15.17
High Stock Price Forecast
$22.50
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+16.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$213.92 million
Pretax Margin
89.21%

Debt

Sales & Book Value

Annual Sales
$331.34 million
Cash Flow
$2.30 per share
Book Value
$8.11 per share

Miscellaneous

Free Float
68,806,000
Market Cap
$911.33 million
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Pavel Raifeld
    Chief Executive Officer
  • Marianne Zhen
    Secretary & Chief Accounting Officer













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2023?

3 brokers have issued twelve-month price targets for Innoviva's stock. Their INVA share price forecasts range from $10.00 to $22.50. On average, they expect the company's share price to reach $15.17 in the next year. This suggests a possible upside of 16.1% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 at the start of the year. Since then, INVA shares have decreased by 1.4% and is now trading at $13.06.
View the best growth stocks for 2023 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.47. The biotechnology company earned $97.86 million during the quarter. Innoviva had a trailing twelve-month return on equity of 18.46% and a net margin of 73.36%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.62%), Dimensional Fund Advisors LP (5.42%), State Street Corp (3.42%), Systematic Financial Management LP (3.21%), Westfield Capital Management Co. LP (2.52%) and Pacer Advisors Inc. (2.35%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $13.06.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $911.33 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.29 on an earnings per share basis.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -